The protection for Intellectual Property Rights (HKI) with higher standards than the one mentioned in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs), known as TRIPs-Plus, has become a crucial legal issue in bilateralism era nowadays. This research is aimed at analyzing the stipulations in TRIPs-Plus in the case of Patent which is mentioned in several Bilateral Free Trade Agreement (BFTAs), analyzing the existence of TRIPs-Plus in BFTA between Indonesia and its business partner countries, and analyzing whether Indonesia needs to revise its Constitution regarding Patent to fulfill such commitment. This was a normative legal research which used constitutional, conceptual, and comparative approaches. The findings show that most of BFTA which are already agreed by developed and developing countries with their business partner countries , in the case of Patent, contain the standards of TRIPs-Plus. Such stipulation is also found in Indonesian Japan Economic Partnership Agreement (IJEPA). However, the revision of Constitution about Patent should be based on not only bilateral commitment, but also national interests. 
standards of IPR protection beyond that specified in the TRIPs Agreement. 9 This TRIPs-Plus provisions is widely agreed in BFTAs between developed countries and developing countries, 10 including Indonesia. It means that IPR norms contained in the TRIPs-Plus is norms suitable for protecting IPR in developed countries, like the United States (US), Japan, European nations, and others. BFTAs tends to promotes developed countries's IPR norms to be implemented in developing countries as well. As the US Trade Promotion Authority stated that the purpose of BFTAs negotiation is to promote IPR rules that "...reflect a standard of protection similar to that found in United States Law." 11 As a response, Drahos argued that standards and norms set out in the United States is a standard that is appropriate to the need of the American economy, which is suitable to the condition of American culture and philosophy, and not an international standard. 12 Similarly, Abbott asserts that if the IP norms suitable to be applied for developed countries, like United States, these norms may not be appropriate when applied in developing countries. 13 This means that the application of the principle of "one size fit all" in IPR protection is not appropriate. Carroll also asserts that the application of the standards and norms of IPR protection based on the principles of "one size fit all" for all countris is not fair. 14 It is also contrary to the general principle of territoriality in IPR protection.
Because of that, the application of IPR protection standards should be adjusted in line with the level of economic and technological development of a country. Journal, Vol 70:6, 2009 , pp. 1362 -1433 According to Reichman, the patent system in the United States today is in a state of "dreadful mess and badly need reform". 15 While in the field of copyright, Patry found that Copyright Act of the United States should be fixed. 16 Interestingly, although the prevailing Acts relating to IPR protection in the United
States from the perspective of American is still lack of perfect and contains a number of problems, such Acts must be implemented in the national jurisdiction of trading partner countries through BFTAs.
It is important to note for developing countries, the application of norms and standards of protection exceeds the TRIPs agreement is not appropriate for the time being, and also be contrary to the obligations of developing countries's governments in the fulfilment of the rights of citizens in specific sectors, like in education, health and agriculture. Despite a number of criticisms, BFTAs is growing rapidly, it is unlike to stopped. 17 Under the Law of Treaties, by signing bilateral agreement, contracting parties to the Agreement have to adjust its national laws inline with the provisions of the Agreement, and this is not exception to Indonesia. On the above basis, it means that Indonesia also required to amend the Act Number 14 of 2001 on Patent. This lead to problems because bilateral commitment does not always in harmony with national interest, or other public interests in the protection of patent.
Statement of the Problems
Based on the background above, the problems of this research can be should Indonesian Patent Act be revised to meet such bilateral commitment?
Research Objective
There are 3 (three) main objectives of this research. Firstly, to analyse the TRIPs-Plus provisions on patent stipulated in the BFTA in general. Secondly, to examine the TRIPs-Plus provisios on patent which have been agreed under BFTAs between Indonesia and its trading partner. And thirdly, to evaluate whether revision in patent Act is needed to meet such bilateral commitment.
Research Method
In principle, the type of this research is normative legal research by using statutory conceptual, and comparative approaches. This statutory approach is done by reviewing all laws and regulations related to the questions of this research, including reviewing international agreements, bilateral agreements, and national legislations relevant to this research issues especially Patent Act. While international conventions covering TRIPs Agreement and Patent Cooperation Treaty (PCT). While conceptual approach used in this research to analyse legal concepts relevant to the questions of this research. Then, comparative approach also used to compare substantial aspects of several BFTAs have agreed between both developed and developing countries. In addition, BFTA between Indonesia and its country trading partner will also be analysed, especially Indonesia-Japan
Economic Partnership Agreement (IJEPA).
This research uses primary and secondary legal sources. The primary sources constitutes authorative sources in nature in the meaning that this source is made by legal authority bodies officially. It consists of legislations, regulations, official records, and treatise in legislations. While secondary legal materials constitutes all forms of publication which is not an official document, which consists of: textbooks, law dictionaries, legal journals, and comments on court decision.
Discussion and Result

TRIPs-Plus Provisions on Patent in the BFTAs between both Developed and Developing Countries in General
Patent protection is unquestionably important. What is cause for concern, however, is the excessive exclusivity and over protection promoted by BFTAs.
This because BFTAs are powerful legal instruments that can impose excessive exclusivity on IP standards, such as: (1) Agreement; 25 (4) the limitation of Compulsary License; 26 (5) the prohibition of marketing approval for a generic drug during the patent term without authorisation from the patent owner; 27 (6) the protection of test data for pharmaceutical products; 28 and (7) the limitation of parallel imports through licence contracts. 29 Analysis of these aspects is outlined as follows:
Firstly, the extension of patent terms. Prior to market entry, pharmaceutical and agrochemical companies are required to obtain official approval from a national health agency. This is normally a lengthy process that can take up to several years. For the purpose of protecting the inventions' exclusive rights, BFTAs are created to link directly with the patent system and the drug administration process to extend the patent term as a compensation for the loss of those rights. Such provisions have been implemented in the US and other developed countries under the "Hatch-Waxman Act." 30 This extension is to allow the patent holder to enjoy the economic benefits that could not be obtained during the approval process. The US-Singapore FTA demands such an extension of patent because of unreasonable delays in the granting of patents. 31 Consequently, the extension of patent terms also delays the introduction of affordable generic drugs, depriving consumers of the benefits of generic competition. This introduces even greater risks to the public health of developing countries, which are already at a disadvantage due to pharmaceutical patents. This extension will also mean that patent-holder will continue to have a monopoly even after the expiration of patent term. Secondly, the limitation of compulsory license. This license provides an important safe guard for public health and now can be found in all IP system. 33 Such licenses are used to balance the rights of patent holders on one hand, and the broader public interest on the other. 34 These non-voluntary licenses are issued by a state, and authorise a third party to produce a cheap generic versions of patented products, with condition that the licensee pays reasonable compensation to the patent holder. The World Health Organization (WHO) has suggested such licenses can be used to ensure that the price of drugs is in harmony with local purchasing power and to 'avoid abuse of patent rights and a national emergency '. 35 Compusory License in countries such as US, Canada, and Brazil have helped to reduce the price of medicines and can be an effective way to restrict the abusive practices of patent holders. 36 On the other hand, from the perspective of researchbased pharmaceutical industries, this licence is a trade distortion because it uses the patents against the will of the patent holders. Accordingly, pharmaceutical companies oppose this approach 37 as it discourage investment, research, and development. 38 It is interesting to note that countries that use compulsory licenses are often subject to economic coersion, although the TRIPs Agreement provides this flexibility. As a result, Doha Declaration on the TRIPs Agreement and Public Health reminded WTO Members to use this legal measure legitimately as a way to improve access to affordable medicines.
Article 31 of the TRIPs Agreement allows member countries to grant compulsory licenses on the basis that they are determinated by each member. It also specifies some reasons why member countries might choose to grant compulsory licenses, whilst recognising that other reasons may exist. However, Interestingly, Palombi argues that the actual meaning of the word "invention" under the Article 27.1 of the TRIPs does not include natural products, natural phenomena and their artificial derivatives. This meaning is consistent with the fundamental principle of patent law: that a patent can only be applied to an "invention" that is "novel", "involve an inventive step" and is "industrially applicable". However, Palombi has confirmed that most biotechnology patents granted in developed countries that "are identical, or materially identical to natural phenomena, that are contrary to and violation of TRIPs". 48 Because of such violations that patents are deemed "void" and are revoked. Accordingly, any provision which prohibit the revocation of "bad patents" contravene prininciple to freely access natural products.
Furthermore, protection of data exclusivity. In most jurisdictions, pharmaceutical and agrochemical products must be registered before entering into market. For the purpose of registration, the companies involved are required to complete a data test regarding the quality, safety and efficacy of the products (known as the test data). Considerable effort goes into compiling such data, which thus needs protection. Under the TRIPs Agreement, all member countries must submit undisclosed data for marketing approval, and to avoid "unfair commercial use" or "disclosure" of such data. 49 The TRIPs does not protect the data exclusivity of the first person who submits marketing approval data to the national drug regulatory authority. 
TRIPs-Plus Provisions on Patent in the BFTA between Indonesia and Its
Trading Partner
Indonesia has already signed an BFTA with Japan in the frame of "Indonesia- The Parties, aiming at further promoting trade and investment, shall grant and ensure adequate, effective and non-discriminatory protection of intellectual property, promote efficiency and transparency in the administration of intellectual property protection system, and provide for measures for the enforcement of intellectual property rights against infringement, counterfeiting and piracy, in accordance with the provisions of this Chapter and the international agreements to which both Parties are parties. Each Party shall ensure that an applicant may, on its own initiative, divide a patent application containing more than one invention into a certain number of divisional patent applications within the time limit provided for in the laws and regulations of the Party. which has the main function to foster the patent application process worldwide.
Still in similar context, Article 112 (4) also states that:
Notwithstanding paragraph 3, a Party which requires, pursuant to relevant provisions of its laws and regulations, the applicant who filed an application for a patent in that Party to furnish a copy of the final decision on an application for a patent of the same or substantially the same invention which the applicant filed in the other Party or in any non-Party, shall examine the application in preference to other applications, if the applicant furnishes the aforementioned copy.
This Article confirms and agrees that patent application filled in a state Party to this agreement must be prioritised if the patent has been registered either in the state or non-state Party, if the application completes the final decision of patent application on the same invention or substantially the same in both Party or non
Party. This provision also contains the same spirit with patent protection through PCT.
Interestingly, this IJEPA does not recognise unwritten "prior art". While in traditional culture like Indonesia, many traditional knowledge that has been developed in the society from generation to generation, particularly for traditional medicinal knowledge. This unwritten "prior art" can be used to reject the novelty of an invention derived from traditional knowledge derived from "missappropriation" or "misuse use of such knowledge. If the cancellation of the novelty of invention is only determined by written "prior art", it is very difficult to prevent misappropriation of traditional knowledge. TRIPs Agreement does not require "prior art" in writing. This means that the TRIPs provides flexibility to the national patent laws to acknowledge the existance of unwritten or spoken language or oral "prior art". However, IJEPA only requires in writing as stipulated as follows:
Each Party shall ensure that any person may provide the administrative authority for patents with information in writing that could deny novelty or inventive step of inventions claimed in patent applications during the pendency of those applications. Each Party shall take the information, as appropriate, into consideration for examining those applications. 63 Furthermore, still in the context of administrative procedure, if patent application is rejected, then after the petition of appeal, the applicant is given the possibility to change the patent application within a specific period of time based on Article 112, as follows:
Each Party shall ensure that an applicant may make amendments to its patent application within a certain period, in accordance with the laws and regulations of the Party, after the filing of its appeal petition with respect to the refusal of such application by the administrative authority for patents. 64 The Article above gives a wider possibility for an invention to be patented and not rejected by the Patent Office of Party to IJEPA. This lead to the emergence of unqualified patents due to lack of novelty and inventive step. Such provision also provide an opportunity for Party, advanced in technology, like Japan for patenting as many inventions invented by citizens in other Party, lack of technological invention.
Moreover, IJEPA sets more stringent regulation related to patent infringement whether for product and process patents as Article 112 (7) stipulates that:
Each Party shall provide that at least the following acts shall be deemed as an infringement of a patent right if performed without the consent of the patent owner: (a) in the case of a patent for an invention of product, acts of manufacturing, assigning, leasing, importing, or offering for assignment or lease, for commercial purposes, things to be used exclusively for the manufacture of the product; and (b) in the case of a patent for an invention of process, acts of manufacturing, assigning, leasing, importing, or offering for assignment or lease, for commercial purposes, things to be used exclusively for the working of such invention.
In addition, IJEPA uses instrument of criminal law, imprisonment and fines for the infringement of all areas of IPR, including patent, as stipulated under
Article 121, which states that:
Each Party shall provide for criminal procedures and penalties to be applied in cases of the infringement of patent rights, rights relating to utility models, industrial designs, trademarks or layout-designs of integrated circuits, copyrights or related rights, or plant breeder's rights, committed willfully and on a commercial scale. Remedies available shall include imprisonment and/or monetary fines sufficient to provide a deterrent, consistently with the level of penalties applied for crimes of a corresponding gravity. After signing the Agreement, usually it is unvitable that national legislation should be amended to comply with this bilateral commitment. The following examines certain Articles in the Indonesia Patent Act 66 that may required to be amended, and whether Indonesia should amend it to the best interest of Indonesia.
Firstly, the provision of Article 3 which stipulated that: (1) an invention shall be considered novel, if at the date of filing of the application said invention is not the same with any previously technological disclusure. (2) It would also be better if this Article also remain unchanged although IJEPA implisitly insists computer program should be protected under Patent Act.
Thirdly, Article 21 of Indonesian Patent Act provides that "Each application can only be filed for one invention, or several inventions that constitute a unity of invention" should also be remain unchanged to avoid and prevent bad patent (lack of quality). Forthly, in the context of rights and obligations of patent holder, Article 16 (1) of the Indonesia Patent Act states that " a patent holder shall have the exclusive right to exploit his Patent and prohibit any other party who without his consent" for product-patent to "makes, makes, uses, sells, imports, rents out, delivers, or makes available for sale or rental or delivery of the patented product".
The above Article shows that Indonesia prohibit paralel importation. Then Article 130 recognised that paralel importatation is criminal offence as it states that:
Any person who deliberately and without rights infringes the rights of a patent holder by committing one of the acts as referred to in Article 16 shall be sentenced to imprisonment of at most 4 (four) years and/or a fine of at most Rp. 500.000.000,00 (five hundred million rupiahs) However, Article 135 (a) excludes from criminal sanction paralel importation for pharmaceutical products after the patent holder put the products into market.
Article 135 (a) stipulates that excepted from criminal provision is "Importation of a pharmaceutical product protected by a patent in Indonesia and that the product has been marketed in a country by the right Patent Holder provided that the product is imported in accordance with the prevailing rules and regulations."
The existance of the above Articles in the context of paralel importation remains unclear, whether Indonesia prohibit paralel importation or not. It is important to note that in the process of amendment, to take into consideration national interest, and not merely to serve bilateral commitment. It means that both national interest and bilateral commitment should be taken into account in the amendment of Patent Act.
Conclusion
The provisions of BFTAs in the field of IPR agreed by both developed and developing countries generally contains TRIPs-Plus Standard for all areas of IPR, including Patent. TRIPs-Plus standard imposed in the BFTAs for developing countries trading partner by developed countries because they demand a higher standart of IPR protection than standards provided in the multilateral agreement.
IJEPA also contain TRIPs-Plus provisions on patent, not only in the substance of protection and administrative procedures, but also stricten its enforcement. IJEPA mandates the establishment of sub-commissons on IPR for operational framework and implementation of the Agreement in order to be adhered by the Parties. The provisions of TRIPs-Plus is very unfavorable for Indonesia as Party that does not produce a lot of inventions in the field of technology and application of patent by national is still very low compared to its trading partner.
As consequence, there are a number of provisions in the field of patent that may require to be adjusted in line with IJEPA, such as the provision on "prior art", the provision on patentable and unpatentable inventions, the provisons on sentencing, the provision on parallel imports, the provisions on exhaustion principle, and others. Accordingly, it is important for Indonesia to consider national interest in the revision of Patent Act and not merely for adherance to bilateral commitment. 
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